Tuberculosis Clinical Trials Consortium Study 35

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

October 12, 2019

Primary Completion Date

December 15, 2024

Study Completion Date

May 15, 2025

Conditions
Latent Tuberculosis
Interventions
DRUG

Rifapentine

Rifapentine. Initial dose will be 25mg/kg. Based on interim analysis, this may be adjusted throughout the study to achieve target exposures. The standalone water-dispersible rifapentine tablet may be used to adjust the rifapentine doses, if needed.

DRUG

Isoniazid

Isoniazid. 25mg/kg

Trial Locations (1)

Unknown

Desmond Tutu TB Center, University of Stellenbosch, Stellenbosch

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

University of Stellenbosch

OTHER

collaborator

Johns Hopkins University

OTHER

collaborator

Sanofi

INDUSTRY

collaborator

University of Cape Town

OTHER

collaborator

Chris Hani Baragwanath Academic Hospital

OTHER

collaborator

Washington D.C. Veterans Affairs Medical Center

FED

lead

Centers for Disease Control and Prevention

FED

NCT03730181 - Tuberculosis Clinical Trials Consortium Study 35 | Biotech Hunter | Biotech Hunter